Marktanalyse - Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017

Global Markets Direct
02.2017
69 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer) — Pipeline Review, H1 2017, provides an overview of the Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline landscape.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer) — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 7, 1, 5 and 1 respectively.

Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Venous Leg Ulcers (Crural ulcer) - Overview

Venous Leg Ulcers (Crural ulcer) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development

Adocia

CardioVascular BioTherapeutics Inc

CytoTools AG

Factor Therapeutics Ltd

FirstString Research Inc

Mallinckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Promore Pharma

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH

Venous Leg Ulcers (Crural ulcer) - Drug Profiles

AUP-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biochaperone PDGF-BB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CL-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CODA-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CureXcell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVBT-141B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EscharEx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LL-37 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-42909 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Statmicoll - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Venous Leg Ulcers (Crural ulcer) - Dormant Projects

Venous Leg Ulcers (Crural ulcer) - Discontinued Products

Venous Leg Ulcers (Crural ulcer) - Product Development Milestones

Featured News & Press Releases

Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update

Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)

Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US

Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board

May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial

Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update

Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers

Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment

Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results

Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications

May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication

Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers

Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results

Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by Factor Therapeutics Ltd, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research Inc, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by Mallinckrodt Plc, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by Promore Pharma, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Venous Leg Ulcers (Crural ulcer) - Pipeline by RMB-Research GmbH, H1 2017

Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1 2017

Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus